8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
Spanish privately owned drugmaker Esteve says it has now obtained pricing and financing for an inhaled treatment for OFF periods in Parkinson's disease, which it launched on the Spanish market in mid-February 2023. 11 March 2023
People with a rare form of lung cancer linked to asbestos exposure have been successfully treated with a combination of Keytruda (pembrolizumab) and chemotherapy. 10 March 2023
Keen to accelerate vaccine drug development and approvals in India, an expert committee of India's Central Drugs Standard Control Organization (CDSCO) met recently to review the research efforts of pharmaceutical companies. 10 March 2023
Pfizer has achieved another regulatory breakthrough, a couple of years on from jointly launching the first mRNA vaccine to reach the market. 10 March 2023
Despite being presenting with briefing documents expressing some concerns about efficacy and safety, the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 11 to 2 in favor of Polivy (polatuzumab vedotin-piiq) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL). 10 March 2023
US biotech Gilead Sciences has now been awarded damages totalling nearly a quarter of a billion dollars in a case that the drugmaker filed against several healthcare clinics, pharmacies, prescribers, and lab testing facilities. 10 March 2023
Some $230 million has now been raised by Ring Therapeutics, a life sciences company founded by Flagship Pioneering with the aim of revolutionizing gene therapy with its commensal virome platform. 10 March 2023
New clinical data from US pharma giant Merck & Co for MK-0616, an investigational oral cholesterol-lowering drug, revealed that it significantly reduced low-density lipoprotein (LDL) cholesterol in adults. 10 March 2023
The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC). 10 March 2023
Zeta Pharma is a fast-growing branded generic pharmaceutical company in the Egyptian market that was established in 2010 and started its production and marketing activities in 2015 on the hepatitis C virus products products Sofocivir, Zetaciver and Sofocivir Plus. 10 March 2023
Effective March 11, Gustavo Pesquin will become the next chief executive (CEO) of Asklepios BioPharmaceutical (AskBio), which was acquired in 2020 by Germany’s Bayer. 9 March 2023
ModeX Therapeutics, an OPKO Health company, has entered into an exclusive worldwide license and collaboration agreement with Merck & Co for the development of MDX-2201, ModeX’ pre-clinical nanoparticle vaccine candidate targeting Epstein-Barr virus (EBV). 9 March 2023
Privately-held Swiss drugmaker Ferring was responsible for two out of the eight biological medicines approved by the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research in 2022. 9 March 2023
Shares of MacroGenics were up 10.9% at $6.10 in early trading today, after the biopharmaceutical company revealed that it has entered into an agreement to sell its royalty interest on future global net sales of Tzield (teplizumab-mzwv) to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200 million. 9 March 2023
Staff at the US Food and Drug Administration (FDA) have prepared a report on the use of Roche’s Polivy (polatuzumab vedotin) alongside Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) in previously untreated large B-cell lymphoma. 9 March 2023
Latest trail results show that solanezumab did not slow the progression of cognitive decline due to Alzheimer's disease (AD) pathology when initiated in individuals with amyloid plaque but no clinical symptoms of the disease, known as the pre-clinical stage of admitted US pharma major Eli Lilly. 9 March 2023
The US subsidiary of Japanese drug major Astellas Pharma today announced disappointing top-line results from the Phase III MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) for patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutated acute myeloid leukemia (AML). 9 March 2023
Cambridge, USA-based clinical-stage biotech QurAlis Corporation has closed an oversubscribed $88 million Series B financing, bringing the total funds raised by the company0 to $143.5 million. 9 March 2023
Biotech companies in the Asia-Pacific (APAC) region are trailing Western rivals in terms of venture capital financing, according to a report from GlobalData. 9 March 2023
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.